Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00069719 | Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients | PHASE2 | COMPLETED | - | — | — | Feb 1, 1999 | Aug 1, 2003 | Aug 5, 2008 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Glaucoma therapy | DRUG | - |
Inclusion Criteria: * Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; * logMAR visual acuity not worse than 0.6. Exclusion Criteria: * Clinically relevant ophthalmic or systemic conditions may be excluded.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |